NRx Pharma: ZYESAMI™ (aviptadil) Helps Prevent Covid Cytokine Storm

 - Sudden Rise in Inflammatory Cytokines (IL-6) Associated with Death in COVID-19 and Other Forms of Acute Respiratory Distress Syndrome

- Data from Randomized Phase 2b/3 Trial Shows Patients Treated with ZYESAMI™ are Significantly Less Likely to Experience IL-6 Cytokine Rise, and Have Improved Survival and Recovery from Respiratory Failure, Compared to Patients Receiving Placebo

- Data Have Been Submitted to US Food and Drug Administration (FDA) as Part of the Emergency Use Authorization (EUA) Application for ZYESAMI™

- NRx Submitting Biomarker Letter of Intent to FDA Based on Phase 2b/3 Data in Support of ZYESAMI™ EUA Application and Future Potential Indications

https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-presents-evidence-zyesami-aviptadil-helps-prevent-cytokine-storm-in-patients-with-covid-19-301336297.html